Tag Archives: FDA

etectRx Gaining Upper Hand in Bioingestible Sensors Market

etectRx and Proteus Digital Health are the only two companies offering Bioingestible sensors

Prescription Digital Therapeutics Market On The Move

PDTs are being developed for a range of conditions, from schizophrenia and depression, to multiple sclerosis and Alzheimer’s, to oncology and GI disorders, and more

Rebates? Strategy from The Football Playbook – The End Around

I failed to discern the implication of the actions proposed by the HHS-FDA Safe Importation Action Plan and the magnitude of its impact to rebates.

CVS Health Initiatives include Chronic Kidney Care

CVS’s objective is to place consumers at the center of its strategy and help them achieve their best health by strengthening health care locally and making it simpler to use and understand

Pharmacogenomic (PGx) Testing Acceptance Growing

Aspects of market change, like pharmacogenomic (PGx) testing, has become increasingly incorporated into medical plan coverage

Telehealth Applications Patient Care

Telehealth Applications Patient Care Rita M. Marcoux, RPh, MBA; F. Randy Vogenberg, PhD, RPh, FASHP June 2016, Vol 7, No 5 – Employers’ Perspective – Value-Based Cancer Care The term telehealth is used interchangeably with telemedicine by some organizations. However, telemedicine is typically associated with the delivery of traditional clinical diagnosis and monitoring by using […]

Oncology Biosimilars: Opportunity or Not?

Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]

Specialty Drug Wave Hitting Medical and Pharmacy Plans Harder: Trends versus reliable benefit strategy to handle the impact through 2020?

Specialty Drug Wave Hitting Medical and Pharmacy Plans Harder: Trends versus reliable benefit strategy to handle the impact through 2020?The U.S. now has two different markets resulting from implementation of the Affordable Care Act (ACA) and resultant trends. Related to specialty or biological drugs, public sector CMS’s forecast of drug spending is somewhat counterintuitive, given […]